Ipca Laboratories

IPCALAB.NSApproved

Ipca Laboratories Ltd. is a prominent, fully integrated Indian pharmaceutical company with a significant global footprint in over 120 countries. Its core strengths lie in its vertical integration, from API manufacturing to finished formulations, particularly in therapeutic segments like anti-malarials, NSAIDs, and anti-diabetics. The company has a diversified business model spanning domestic formulations, international branded generics, and API exports, and is strategically focused on expanding its presence in regulated markets like the US while navigating complex regulatory landscapes.

Market Cap

$4.1B

Employees

10000-12000

Focus

Biotech

IPCALAB.NS · Stock Price

USD 1527.00+572.25 (+59.94%)

Historical price data

AI Company Overview

Technology Platform

Vertically integrated model with core expertise in complex API synthesis and formulation development across a wide range of dosage forms, with a historical focus on anti-malarial and NSAID chemistry.

Pipeline Snapshot

31 drugs in pipeline

Drug	Indication	Stage
Lamotrigine Tablets 25 mg + Lamotrigine	Fasting State	Phase 1
Metformin Hydrochloride Extended-Release Tablets USP 750 mg + GLUCOPHAGE®XR	Fasting	Phase 1
Levocetirizine Dihydrochloride tablets 5 mg + Levocetirizine Dihydrochloride	Fed	Phase 1
Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride	Fasting State	Phase 1
Metformin Hydrochloride Extended-Release Tablets USP 750 + GLUCOPHAGE®XR tablet ...	Fasting	Phase 1

Funding History

IPOUndisclosedUndisclosedSep 15, 1995

FDA Approved Drugs

ETODOLACANDAAug 1, 2024

ETODOLACANDAMay 1, 2024

ONDANSETRONANDAOct 30, 2023

Opportunities

Significant growth opportunity lies in the full resolution of US FDA compliance issues, enabling a strong pipeline of ANDA launches in the world's largest generics market.

Expansion in emerging markets and the development of a biosimilars portfolio offer additional long-term growth vectors.

Risk Factors

The primary risk is regulatory non-compliance, particularly ongoing US FDA warnings on manufacturing facilities, which can restrict market access.

Other key risks include intense pricing pressure in generics, reliance on anti-malarial products, and patent litigation in key markets.

Competitive Landscape

Ipca faces intense competition from large Indian peers (Sun Pharma, Dr. Reddy's, Cipla) domestically and in global generics, and from global generic giants like Teva. Its differentiation stems from vertical integration, cost leadership in API manufacturing, and strong brand equity in specific therapeutic areas like anti-malarials and NSAIDs within key markets.

Publications

Patents

Pipeline

FDA Approvals